Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 13/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070691 | 0.85 | TTK (0.61) | TTK | |
| SCHEMBL13731243 | 0.82 | KLKB1 (0.46) | TTK | |
| SCHEMBL13731580 | 0.80 | TTK (0.48) | TTKAURKBPIK3CDPIK3CGPIK3CA | |
| SCHEMBL1933562 | 0.79 | TTK (0.62) | TTKPIK3CDPIK3CG | |
| SCHEMBL18896707 | 0.78 | TTK (0.46) | TTKPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL1932313 | 0.78 | TTK (0.60) | TTKPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL13731733 | 0.77 | PIK3CD (0.51) | TTKPIK3CDPIK3CGPIK3CA | |
| SCHEMBL9998764 | 0.76 | MET (0.48) | TTK | |
| SCHEMBL12068441 | 0.76 | TTK (0.49) | TTK | |
| SCHEMBL9997048 | 0.75 | PIK3CG (0.47) | TTKPIK3CDPIK3CGPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699575-B1 | TRIAZOLOPYRIDINES | BAYER IP GMBH (DE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2699575-B1 | TRIAZOLOPYRIDINES | BAYER IP GMBH (DE) | 2015-03-25 | — | — | EP | disclosed |
| US-20140120087-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-01 | — | — | US | disclosed |
| EP-2699575-A1 | TRIAZOLOPYRIDINES | Bayer Intellectual Property GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143329-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140120087-A1 | TRIAZOLOPYRIDINES | QDPR, TBXA2R, KCNJ11 | TTK 2059/4885MAPK8 4300/4885LCK 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.